aTyr, The Hong Kong University of Science and Technology, The Scripps Research Institute and Stanford University Join in the Discovery of a New Class of Human Proteins
July 17, 2014aTyr Pharma, aTyr’s subsidary Pangu Biopharma, The Scripps Research Institute of La Jolla and Florida, The Hong Kong University of Science and Technology and Stanford Univeristy announced the discovery of a new class of human proteins.
More »
Adynxx Initiates Phase 2 Dose-Ranging Study of AYX1, Lead Compound for the Prevention of Post-Surgical Pain
July 16, 2014Adynxx announced the first patient was dosed in their Phase 2 dose-ranging study, ADYX-003. This study investigates AYXI, a drug candidate for the prevention of post-surgical pain, following their recently completed ADYX-002 proof-of-concept study.
More »
aTyr Pharma Announces Publication of a Rare Muscle Disease Associated with Regulation of a Potential Physiocrine
July 14, 2014aTyr Pharma announced the scientific publication of a splice variant of a tRNA synthetase in association with a rare muscle disease, published in the Journal of Biological Chemistry.
More »